Loading…

Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines

New therapeutic drug for breast cancer (BRCA), especially triple negative BRCA (TNBC), is urgently needed. Even though 2-(4-morpholinoanilino)-6-cyclohexylaminopurine (reversine) is an aurora kinase inhibitor, it also inhibits some cancer cells and human BRCA cells. However, the potential roles of r...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell international 2019-06, Vol.19 (1), p.166-166, Article 166
Main Authors: Huang, Di, Huang, Yu, Huang, Zisheng, Weng, Jiefeng, Zhang, Shuai, Gu, Weili
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c594t-71abc2c2162f5392e9705ddf5fd0efc26530798aafcd2a8ff1e634cd13d66d53
cites cdi_FETCH-LOGICAL-c594t-71abc2c2162f5392e9705ddf5fd0efc26530798aafcd2a8ff1e634cd13d66d53
container_end_page 166
container_issue 1
container_start_page 166
container_title Cancer cell international
container_volume 19
creator Huang, Di
Huang, Yu
Huang, Zisheng
Weng, Jiefeng
Zhang, Shuai
Gu, Weili
description New therapeutic drug for breast cancer (BRCA), especially triple negative BRCA (TNBC), is urgently needed. Even though 2-(4-morpholinoanilino)-6-cyclohexylaminopurine (reversine) is an aurora kinase inhibitor, it also inhibits some cancer cells and human BRCA cells. However, the potential roles of reversine as a novel therapeutic agent for the treatment of BRCA remains unknown and must be further investigation. Thus, the relationship of reversine to aurora kinase in BCRA has not been reported. The relationship between AURKB and survival rate in BRCA has never been reported. Herein, we tested the roles of reversine on different BRCA cell line subtypes. We also investigated the relationship between AURKB and survival rate in BRCA as well as reversine to Aurora kinase expression in BCRA cell lines, including TNBC subtype, 4T1, MDA-MB-231, and luminal subtype MCF-7. Cell viability and apoptosis were detected using Cell Counting Kit-8 and flow cytometry analysis, respectively. Apoptotic and tumor-related proteins were tested using Western blot analysis. Important microRNAs that regulate BRCA were analyzed using RT-PCR. UALCAN public databases were used to analyze the targeted gene profiles, and the PROGgeneV2 database was used to study the prognostic implications of genes. Reversine inhibits cell proliferation and induces cell apoptosis by modulating caspase-3 and bax/bcl-2 among the three cell lines. Data from the UALCAN public database show that BRCA tissues expressed high gene levels of , and compared with the normal tissue. Among the over-expressed genes in BRCA, ranks 9th in TNBC, 49th in luminal subtype, and 48th in HER2 subtype. High level in BRCA is highly related to the low survival rate in patients displayed in 18 databases searched via PROGgeneV2. The protein levels of aurora B kinase (Aurora B), which is encoded by gene, are highly suppressed by reversine in the three cell lines. The tumor-related proteins TGF-β1, TIMP1, and MMP9 are partially suppressed by reversine but with different sensitivity in the three cell lines. The reversine-affected microRNAs, such as miR129-5p, miR-199a-3p, and miR-3960, in MDA-MB-231 cell line might be the research targets in TNBC regulation. In BRCA, the level of are over-expressed and is related to low survival rate. Reversine contributes to anti-growth effect in BRCA cell lines, especially for TNBC, by modulating the aurora B. However, the invasiveness, metastasis, and anti-tumor effects of reversine in vivo and in
doi_str_mv 10.1186/s12935-019-0885-z
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_ccad0b4c4bf84f3c8820da912829ccfc</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_ccad0b4c4bf84f3c8820da912829ccfc</doaj_id><sourcerecordid>2243407000</sourcerecordid><originalsourceid>FETCH-LOGICAL-c594t-71abc2c2162f5392e9705ddf5fd0efc26530798aafcd2a8ff1e634cd13d66d53</originalsourceid><addsrcrecordid>eNpdkk9v1DAQxSMEoqXwAbggS1x6Cfhv4lyQdlfQVlRCWpWzNbHHJUvWXuxkgR755CTdUrWcPPK899PM6BXFa0bfMaar95nxRqiSsqakWqvy5klxzGStSq6r-umD-qh4kfOGUlbrij4vjgTjUiolj4s_a-xh6GIg0ZPF1_XnJYl7TCX-2iXMeW4MkfTxJ8lj2nd76EmCAUkXyHK1XhAIjiScHLkLWG6jGyccOgJjignIknzvAuRbfZsQ8kAsBIuJWOx70k-m_LJ45qHP-OruPSmuPn28Wp2Xl1_OLlaLy9KqRg5lzaC13HJWca9Ew7GpqXLOK-8oessrJWjdaABvHQftPcNKSOuYcFXllDgpLg5YF2FjdqnbQvptInTm9iOmawNp6GyPxlpwtJVWtl5LL6zWnDpoGNe8sdbbifXhwNqN7RadxTAk6B9BH3dC981cx72plOZKzsOc3gFS_DFiHsy2y_NJIGAcs-FcalGrupmlb_-TbuKYwnSpWSUkrSmlk4odVDbFnBP6-2EYNXNYzCEsZgqLmcNibibPm4db3Dv-pUP8BRO0vR8</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2243407000</pqid></control><display><type>article</type><title>Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines</title><source>PubMed (Medline)</source><source>Publicly Available Content (ProQuest)</source><creator>Huang, Di ; Huang, Yu ; Huang, Zisheng ; Weng, Jiefeng ; Zhang, Shuai ; Gu, Weili</creator><creatorcontrib>Huang, Di ; Huang, Yu ; Huang, Zisheng ; Weng, Jiefeng ; Zhang, Shuai ; Gu, Weili</creatorcontrib><description>New therapeutic drug for breast cancer (BRCA), especially triple negative BRCA (TNBC), is urgently needed. Even though 2-(4-morpholinoanilino)-6-cyclohexylaminopurine (reversine) is an aurora kinase inhibitor, it also inhibits some cancer cells and human BRCA cells. However, the potential roles of reversine as a novel therapeutic agent for the treatment of BRCA remains unknown and must be further investigation. Thus, the relationship of reversine to aurora kinase in BCRA has not been reported. The relationship between AURKB and survival rate in BRCA has never been reported. Herein, we tested the roles of reversine on different BRCA cell line subtypes. We also investigated the relationship between AURKB and survival rate in BRCA as well as reversine to Aurora kinase expression in BCRA cell lines, including TNBC subtype, 4T1, MDA-MB-231, and luminal subtype MCF-7. Cell viability and apoptosis were detected using Cell Counting Kit-8 and flow cytometry analysis, respectively. Apoptotic and tumor-related proteins were tested using Western blot analysis. Important microRNAs that regulate BRCA were analyzed using RT-PCR. UALCAN public databases were used to analyze the targeted gene profiles, and the PROGgeneV2 database was used to study the prognostic implications of genes. Reversine inhibits cell proliferation and induces cell apoptosis by modulating caspase-3 and bax/bcl-2 among the three cell lines. Data from the UALCAN public database show that BRCA tissues expressed high gene levels of , and compared with the normal tissue. Among the over-expressed genes in BRCA, ranks 9th in TNBC, 49th in luminal subtype, and 48th in HER2 subtype. High level in BRCA is highly related to the low survival rate in patients displayed in 18 databases searched via PROGgeneV2. The protein levels of aurora B kinase (Aurora B), which is encoded by gene, are highly suppressed by reversine in the three cell lines. The tumor-related proteins TGF-β1, TIMP1, and MMP9 are partially suppressed by reversine but with different sensitivity in the three cell lines. The reversine-affected microRNAs, such as miR129-5p, miR-199a-3p, and miR-3960, in MDA-MB-231 cell line might be the research targets in TNBC regulation. In BRCA, the level of are over-expressed and is related to low survival rate. Reversine contributes to anti-growth effect in BRCA cell lines, especially for TNBC, by modulating the aurora B. However, the invasiveness, metastasis, and anti-tumor effects of reversine in vivo and in vitro must be further investigated.</description><identifier>ISSN: 1475-2867</identifier><identifier>EISSN: 1475-2867</identifier><identifier>DOI: 10.1186/s12935-019-0885-z</identifier><identifier>PMID: 31244554</identifier><language>eng</language><publisher>England: BioMed Central</publisher><subject>Apoptosis ; AURKB ; Aurora B ; Aurora B protein ; Aurora kinase ; BAX protein ; Bcl-2 protein ; BRCA ; Breast cancer ; Cancer therapies ; Caspase ; Caspase-3 ; Cell cycle ; Cell lines ; Cell proliferation ; Cell viability ; Chemical compounds ; Enzyme inhibitors ; ErbB-2 protein ; Fibroblasts ; Flow cytometry ; Gelatinase B ; Genes ; Invasiveness ; Kinases ; Medical prognosis ; Metastases ; MicroRNAs ; miRNA ; Overexpression ; Polymerase chain reaction ; Polyploidy ; Primary Research ; Proteins ; Reversine ; Stem cells ; Survival ; Tissue inhibitor of metalloproteinase 1 ; Transforming growth factor-b1 ; Triple-negative breast cancer cells ; Tumor cell lines ; Viability</subject><ispartof>Cancer cell international, 2019-06, Vol.19 (1), p.166-166, Article 166</ispartof><rights>2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c594t-71abc2c2162f5392e9705ddf5fd0efc26530798aafcd2a8ff1e634cd13d66d53</citedby><cites>FETCH-LOGICAL-c594t-71abc2c2162f5392e9705ddf5fd0efc26530798aafcd2a8ff1e634cd13d66d53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582545/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2243407000?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31244554$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Di</creatorcontrib><creatorcontrib>Huang, Yu</creatorcontrib><creatorcontrib>Huang, Zisheng</creatorcontrib><creatorcontrib>Weng, Jiefeng</creatorcontrib><creatorcontrib>Zhang, Shuai</creatorcontrib><creatorcontrib>Gu, Weili</creatorcontrib><title>Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines</title><title>Cancer cell international</title><addtitle>Cancer Cell Int</addtitle><description>New therapeutic drug for breast cancer (BRCA), especially triple negative BRCA (TNBC), is urgently needed. Even though 2-(4-morpholinoanilino)-6-cyclohexylaminopurine (reversine) is an aurora kinase inhibitor, it also inhibits some cancer cells and human BRCA cells. However, the potential roles of reversine as a novel therapeutic agent for the treatment of BRCA remains unknown and must be further investigation. Thus, the relationship of reversine to aurora kinase in BCRA has not been reported. The relationship between AURKB and survival rate in BRCA has never been reported. Herein, we tested the roles of reversine on different BRCA cell line subtypes. We also investigated the relationship between AURKB and survival rate in BRCA as well as reversine to Aurora kinase expression in BCRA cell lines, including TNBC subtype, 4T1, MDA-MB-231, and luminal subtype MCF-7. Cell viability and apoptosis were detected using Cell Counting Kit-8 and flow cytometry analysis, respectively. Apoptotic and tumor-related proteins were tested using Western blot analysis. Important microRNAs that regulate BRCA were analyzed using RT-PCR. UALCAN public databases were used to analyze the targeted gene profiles, and the PROGgeneV2 database was used to study the prognostic implications of genes. Reversine inhibits cell proliferation and induces cell apoptosis by modulating caspase-3 and bax/bcl-2 among the three cell lines. Data from the UALCAN public database show that BRCA tissues expressed high gene levels of , and compared with the normal tissue. Among the over-expressed genes in BRCA, ranks 9th in TNBC, 49th in luminal subtype, and 48th in HER2 subtype. High level in BRCA is highly related to the low survival rate in patients displayed in 18 databases searched via PROGgeneV2. The protein levels of aurora B kinase (Aurora B), which is encoded by gene, are highly suppressed by reversine in the three cell lines. The tumor-related proteins TGF-β1, TIMP1, and MMP9 are partially suppressed by reversine but with different sensitivity in the three cell lines. The reversine-affected microRNAs, such as miR129-5p, miR-199a-3p, and miR-3960, in MDA-MB-231 cell line might be the research targets in TNBC regulation. In BRCA, the level of are over-expressed and is related to low survival rate. Reversine contributes to anti-growth effect in BRCA cell lines, especially for TNBC, by modulating the aurora B. However, the invasiveness, metastasis, and anti-tumor effects of reversine in vivo and in vitro must be further investigated.</description><subject>Apoptosis</subject><subject>AURKB</subject><subject>Aurora B</subject><subject>Aurora B protein</subject><subject>Aurora kinase</subject><subject>BAX protein</subject><subject>Bcl-2 protein</subject><subject>BRCA</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Caspase</subject><subject>Caspase-3</subject><subject>Cell cycle</subject><subject>Cell lines</subject><subject>Cell proliferation</subject><subject>Cell viability</subject><subject>Chemical compounds</subject><subject>Enzyme inhibitors</subject><subject>ErbB-2 protein</subject><subject>Fibroblasts</subject><subject>Flow cytometry</subject><subject>Gelatinase B</subject><subject>Genes</subject><subject>Invasiveness</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>MicroRNAs</subject><subject>miRNA</subject><subject>Overexpression</subject><subject>Polymerase chain reaction</subject><subject>Polyploidy</subject><subject>Primary Research</subject><subject>Proteins</subject><subject>Reversine</subject><subject>Stem cells</subject><subject>Survival</subject><subject>Tissue inhibitor of metalloproteinase 1</subject><subject>Transforming growth factor-b1</subject><subject>Triple-negative breast cancer cells</subject><subject>Tumor cell lines</subject><subject>Viability</subject><issn>1475-2867</issn><issn>1475-2867</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkk9v1DAQxSMEoqXwAbggS1x6Cfhv4lyQdlfQVlRCWpWzNbHHJUvWXuxkgR755CTdUrWcPPK899PM6BXFa0bfMaar95nxRqiSsqakWqvy5klxzGStSq6r-umD-qh4kfOGUlbrij4vjgTjUiolj4s_a-xh6GIg0ZPF1_XnJYl7TCX-2iXMeW4MkfTxJ8lj2nd76EmCAUkXyHK1XhAIjiScHLkLWG6jGyccOgJjignIknzvAuRbfZsQ8kAsBIuJWOx70k-m_LJ45qHP-OruPSmuPn28Wp2Xl1_OLlaLy9KqRg5lzaC13HJWca9Ew7GpqXLOK-8oessrJWjdaABvHQftPcNKSOuYcFXllDgpLg5YF2FjdqnbQvptInTm9iOmawNp6GyPxlpwtJVWtl5LL6zWnDpoGNe8sdbbifXhwNqN7RadxTAk6B9BH3dC981cx72plOZKzsOc3gFS_DFiHsy2y_NJIGAcs-FcalGrupmlb_-TbuKYwnSpWSUkrSmlk4odVDbFnBP6-2EYNXNYzCEsZgqLmcNibibPm4db3Dv-pUP8BRO0vR8</recordid><startdate>20190618</startdate><enddate>20190618</enddate><creator>Huang, Di</creator><creator>Huang, Yu</creator><creator>Huang, Zisheng</creator><creator>Weng, Jiefeng</creator><creator>Zhang, Shuai</creator><creator>Gu, Weili</creator><general>BioMed Central</general><general>BMC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TM</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20190618</creationdate><title>Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines</title><author>Huang, Di ; Huang, Yu ; Huang, Zisheng ; Weng, Jiefeng ; Zhang, Shuai ; Gu, Weili</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c594t-71abc2c2162f5392e9705ddf5fd0efc26530798aafcd2a8ff1e634cd13d66d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Apoptosis</topic><topic>AURKB</topic><topic>Aurora B</topic><topic>Aurora B protein</topic><topic>Aurora kinase</topic><topic>BAX protein</topic><topic>Bcl-2 protein</topic><topic>BRCA</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Caspase</topic><topic>Caspase-3</topic><topic>Cell cycle</topic><topic>Cell lines</topic><topic>Cell proliferation</topic><topic>Cell viability</topic><topic>Chemical compounds</topic><topic>Enzyme inhibitors</topic><topic>ErbB-2 protein</topic><topic>Fibroblasts</topic><topic>Flow cytometry</topic><topic>Gelatinase B</topic><topic>Genes</topic><topic>Invasiveness</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>MicroRNAs</topic><topic>miRNA</topic><topic>Overexpression</topic><topic>Polymerase chain reaction</topic><topic>Polyploidy</topic><topic>Primary Research</topic><topic>Proteins</topic><topic>Reversine</topic><topic>Stem cells</topic><topic>Survival</topic><topic>Tissue inhibitor of metalloproteinase 1</topic><topic>Transforming growth factor-b1</topic><topic>Triple-negative breast cancer cells</topic><topic>Tumor cell lines</topic><topic>Viability</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Di</creatorcontrib><creatorcontrib>Huang, Yu</creatorcontrib><creatorcontrib>Huang, Zisheng</creatorcontrib><creatorcontrib>Weng, Jiefeng</creatorcontrib><creatorcontrib>Zhang, Shuai</creatorcontrib><creatorcontrib>Gu, Weili</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Cancer cell international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Di</au><au>Huang, Yu</au><au>Huang, Zisheng</au><au>Weng, Jiefeng</au><au>Zhang, Shuai</au><au>Gu, Weili</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines</atitle><jtitle>Cancer cell international</jtitle><addtitle>Cancer Cell Int</addtitle><date>2019-06-18</date><risdate>2019</risdate><volume>19</volume><issue>1</issue><spage>166</spage><epage>166</epage><pages>166-166</pages><artnum>166</artnum><issn>1475-2867</issn><eissn>1475-2867</eissn><abstract>New therapeutic drug for breast cancer (BRCA), especially triple negative BRCA (TNBC), is urgently needed. Even though 2-(4-morpholinoanilino)-6-cyclohexylaminopurine (reversine) is an aurora kinase inhibitor, it also inhibits some cancer cells and human BRCA cells. However, the potential roles of reversine as a novel therapeutic agent for the treatment of BRCA remains unknown and must be further investigation. Thus, the relationship of reversine to aurora kinase in BCRA has not been reported. The relationship between AURKB and survival rate in BRCA has never been reported. Herein, we tested the roles of reversine on different BRCA cell line subtypes. We also investigated the relationship between AURKB and survival rate in BRCA as well as reversine to Aurora kinase expression in BCRA cell lines, including TNBC subtype, 4T1, MDA-MB-231, and luminal subtype MCF-7. Cell viability and apoptosis were detected using Cell Counting Kit-8 and flow cytometry analysis, respectively. Apoptotic and tumor-related proteins were tested using Western blot analysis. Important microRNAs that regulate BRCA were analyzed using RT-PCR. UALCAN public databases were used to analyze the targeted gene profiles, and the PROGgeneV2 database was used to study the prognostic implications of genes. Reversine inhibits cell proliferation and induces cell apoptosis by modulating caspase-3 and bax/bcl-2 among the three cell lines. Data from the UALCAN public database show that BRCA tissues expressed high gene levels of , and compared with the normal tissue. Among the over-expressed genes in BRCA, ranks 9th in TNBC, 49th in luminal subtype, and 48th in HER2 subtype. High level in BRCA is highly related to the low survival rate in patients displayed in 18 databases searched via PROGgeneV2. The protein levels of aurora B kinase (Aurora B), which is encoded by gene, are highly suppressed by reversine in the three cell lines. The tumor-related proteins TGF-β1, TIMP1, and MMP9 are partially suppressed by reversine but with different sensitivity in the three cell lines. The reversine-affected microRNAs, such as miR129-5p, miR-199a-3p, and miR-3960, in MDA-MB-231 cell line might be the research targets in TNBC regulation. In BRCA, the level of are over-expressed and is related to low survival rate. Reversine contributes to anti-growth effect in BRCA cell lines, especially for TNBC, by modulating the aurora B. However, the invasiveness, metastasis, and anti-tumor effects of reversine in vivo and in vitro must be further investigated.</abstract><cop>England</cop><pub>BioMed Central</pub><pmid>31244554</pmid><doi>10.1186/s12935-019-0885-z</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1475-2867
ispartof Cancer cell international, 2019-06, Vol.19 (1), p.166-166, Article 166
issn 1475-2867
1475-2867
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_ccad0b4c4bf84f3c8820da912829ccfc
source PubMed (Medline); Publicly Available Content (ProQuest)
subjects Apoptosis
AURKB
Aurora B
Aurora B protein
Aurora kinase
BAX protein
Bcl-2 protein
BRCA
Breast cancer
Cancer therapies
Caspase
Caspase-3
Cell cycle
Cell lines
Cell proliferation
Cell viability
Chemical compounds
Enzyme inhibitors
ErbB-2 protein
Fibroblasts
Flow cytometry
Gelatinase B
Genes
Invasiveness
Kinases
Medical prognosis
Metastases
MicroRNAs
miRNA
Overexpression
Polymerase chain reaction
Polyploidy
Primary Research
Proteins
Reversine
Stem cells
Survival
Tissue inhibitor of metalloproteinase 1
Transforming growth factor-b1
Triple-negative breast cancer cells
Tumor cell lines
Viability
title Relation of AURKB over-expression to low survival rate in BCRA and reversine-modulated aurora B kinase in breast cancer cell lines
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T21%3A35%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relation%20of%20AURKB%20over-expression%20to%20low%20survival%20rate%20in%20BCRA%20and%20reversine-modulated%20aurora%20B%20kinase%20in%20breast%20cancer%20cell%20lines&rft.jtitle=Cancer%20cell%20international&rft.au=Huang,%20Di&rft.date=2019-06-18&rft.volume=19&rft.issue=1&rft.spage=166&rft.epage=166&rft.pages=166-166&rft.artnum=166&rft.issn=1475-2867&rft.eissn=1475-2867&rft_id=info:doi/10.1186/s12935-019-0885-z&rft_dat=%3Cproquest_doaj_%3E2243407000%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c594t-71abc2c2162f5392e9705ddf5fd0efc26530798aafcd2a8ff1e634cd13d66d53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2243407000&rft_id=info:pmid/31244554&rfr_iscdi=true